We also treat benign hemangiomas with 4x5 Gy(RBE).
Low-grade glioma of the brain and spinal cord
Chondrosarcoma and chordoma of the skull base and spinal cord
This form of tumor develops in bone or connective tissues, or both. It grows slowly and metastasizes rarely, but destroys the usually sensitive and often vital neighboring structures. The proton beam penetrates tissues to a calculable depth, delivering the greatest, controlled dose of radiation at the end of the beam, the so-called Bragg Peak. This characteristic has been used now for many years to treat cordomas and chondrosarcomas of the skull base and spinal cord. Most of these cases were treated at the Harvard Cyclotron / Massachusetts General Hospital. In comparison to photon therapy, proton therapy has improved local tumor control rates for chondrosarcoma from approximately 40 % to over 80 % and for chordoma from less than 5 % to more than 50 %.
Developed at PSI, the IMPT technique (Intensity Modulated Proton Therapy) was implemented for the first time in 1999 to treat a young man with chondrosarcoma of the thoracic spine. This technique enabled the greatest possible protection of the spinal cord. Today, 20 years after completing the treatment, this patient is able to lead a completely normal life. This case illustrates clearly why chondrosarcoma and chordoma, besides melanoma of the eye, are considered clearly undisputed indications for proton therapy.
For tumors of the so-called soft tissue sarcoma type and diagnosed as inoperable or removable only through radical surgery which will result in a great loss of bodily function, PSI offers a course of pre-operative or definitive proton therapy in combination with hyperthermia therapy under the leadership of the Radio-Oncology Department of the Cantonal Hospital in Aarau. This treatment is offered within the framework of a prospective clinical trial (Short title: HYPROSAR, Trial description in the Clinicaltrials Registry), which has been approved by the Ethics Commission and is being carried out under close collaboration with the University Hospital of Zürich. All treatment requests from sarcoma patients or their referring physicians must be introduced with appropriate documentation at the sarcoma board of the Balgrist University Hospital in Zürich. A panel of experts will then decide if the patient is a suitable candidate for the trial. For further information, please contact Dr. Walser (firstname.lastname@example.org) (Datta et al. 2016).
Head & Neck Tumors
At PSI almost all the children and adolescents are treated within the framework of a study or according to a study protocol. All are asked to participate in one prospective observation study:
- A survey of the quality of life after proton therapy (Pediatric Quality of Life = Pedqol questionnaire); a cooperative project with the University of Bonn in Germany;